JASTLabs

​J-112 proprietary recipe is the first to utilize oxytocin (not to be confused with OxyContin) and may provide relief from menopause and diminished libido.

Unlike current treatment options, JL-112 does not use estrogen or progestin.

JL-112 is a white, odorless cream, applied in tiny amounts before vaginal intercourse. The cream elicits improve natural lubrication, plus psychological effects that enhance sexual pleasure and foster conditions for improved emotional pleasures.

JL-112 makes it possible for women to rejuvenate the moisture within the vaginal mucosa, and returns the ability to climax with more frequency and pleasure, no matter the age.

JL-112 is administered transdermally, which equates to fewer complications than the competitive synthetic drugs that are taken orally.

JL-112 is the first product in the category to allow the body to receive the appropriate hormones without passing through the liver. This method is safer, faster, and more effective.

Current Status

JL-112  is in continuous laboratory testing to ensure our formulation is optimized both at a refrigerated and room temperature state.

United States Patent application has been filed. Serial number PCT/CA 2025/050571 under the heading of “Topical compositions for treating vaginitis”.

Jastlabs is a negotiation with various regulatory approved entities to engage in pre-IND (investigational new drug) meetings with the FDA to register its application under a 505 B (2) in United States.

JASTLABS is on the path to become a public listed issuer and will take the next steps to engage its funding in Q3 2025.

JASTLABS is in the process of raising $20(USD) million to achieve our goals. We are raising these funds by utilizing a (regulation "A") in the USA. The application process is in motion to be approved by SEC securities commission for "public issuer" listing.